Skip to main content
. 2015 Sep 3;2015:464570. doi: 10.1155/2015/464570

Table 4.

Univariate and multivariate analysis of disease-free survival.

Characteristics N Univariatea Multivariate
HR 95% CI P value HR 95% CI P value
Low-volume surgeon 445b 1.000     1.000    
High-volume surgeon 316b 0.566 0.44–0.74 <0.001 0.736 0.55–0.98 0.04
Age in years       0.01     <0.001
 <50 41 1.000     1.000    
 50–75 486 1.052 0.61–1.80   1.261 0.67–2.37  
 >75 234 1.304 1.16–1.49   2.034 1.01–4.08  
ASA-classification [16]       <0.001     0.05
 1 158 1.000     1.000    
 2 410 0.938 0.68–1.29   0.914 0.63–1.33  
 3 181 1.547 1.09–2.19   1.301 0.86–1.97  
 4 25 2.567 1.65–4.62   1.507 1.05–2.86  
Urogenital comorbidity 66 1.521 1.07–2.17 0.02 1.174 0.69–1.47 0.43
Open surgical technique 253 1.000     1.000    
Laparoscopic 508 0.518 0.41–0.65 <0.001 0.752 0.55–1.03 0.08
No conversion 396 1.000     1.000    
Conversion (laparoscopy only) 112 1.380 1.03–1.86 0.03 1.337 0.92–1.95 0.13
Elapsed time of the surgery 761 1.003 1.00–1.01 0.02 1.001 0.99–1.01 0.43
Blood loss intraoperatively 761 1.001 1.00–1.01 <0.001 1.000 0.99–1.00 0.20
Tumor stagec       <0.001     0.04
 1 50 1.000     1.000    
 2 153 1.293 0.63–2.67   1.307 0.59–2.91  
 3 489 2.549 1.31–4.97   1.666 0.79–3.52  
 4 58 6.609 3.21–13.6   2.814 1.21–6.54  
Nodal stagec       <0.001     <0.001
 0 439 1.000     1.000    
 1 216 2.484 1.91–3.23   1.769 1.28–2.46  
 2 106 4.791 3.57–6.43   2.484 1.51–4.10  
Metastatic stagec       <0.001     <0.001
 0 684 1.000     1.000    
 1 77 9.697 7.29–12.9   7.093 4.99–10.1  
Positive lymph nodes 761 1.117 1.09–1.14 <0.001 1.031 0.98–1.08 0.21
Resection margins       <0.001     0.29
 Complete resection (R0) 731 1.000     1.000    
 Microscopically irradical (R1) 19 2.955 1.76–4.97   1.200 0.60–2.38  
 Macroscopically irradical (R2) 11 3.080 1.58–6.00   0.551 0.23–1.32  
Length of hospital-stay 761 1.012 1.01–1.02 <0.001 1.004 0.99–1.01 0.39
No adverse event 656 1.000     1.000    
Adverse event 105 1.664 1.24–2.23 0.01 1.069 0.69–1.65 0.76
No adjuvant chemotherapy 546 1.000     1.000    
Adjuvant chemotherapy 215 2.104 1.67–2.65 <0.001 1.376 0.98–1.93 0.06

aOnly significant factors listed; b13 patients lost to follow-up, 8 low-volume patients, and 5 high-volume patients; caccording to the AJCC TNM-staging system [17].